SLC5A6: A Potential Drug Target and Biomarker (G8884)

Target Name: SLC5A6

NCBI ID: G8884

SLC5A6

SLC5A6: A Potential Drug Target and Biomarker

SLC5A6 (Simple Localized Calbindin-like 6) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the Calbindin family of proteins, which are known for their ability to bind to and label target tissues and organs due to their high affinity for calcium ions. SLC5A6 has been identified as a potential drug target or biomarker due to its unique structure and expression pattern, as well as its involvement in several diseases, including cancer, neurodegenerative diseases, and gastrointestinal disorders.

SLC5A6 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. It is characterized by a unique structure that consists of a long N-terminus, a transmembrane region, and a C-terminus. The N-terminus of SLC5A6 contains a unique domain that is composed of a stretch of amino acids that is similar to the N-terminus of calbindin proteins. This domain is known as the calbindin-like domain and is responsible for the protein's ability to bind to and label target tissues and organs due to its high affinity for calcium ions.

One of the unique features of SLC5A6 is its expression pattern. It is highly expressed in the brain and pancreas, and is also expressed in other tissues, such as the gastrointestinal tract and liver. This suggests that SLC5A6 may be involved in a variety of biological processes that are relevant to these tissues, including neurotransmission, insulin secretion, and immune response.

In addition to its expression pattern, SLC5A6 has also been identified as a potential drug target due to its involvement in several diseases. For example, SLC5A6 has been shown to be overexpressed in several types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting SLC5A6 may be a promising strategy for the development of new treatments for these diseases.

SLC5A6 has also been identified as a potential biomarker for several gastrointestinal disorders, including inflammatory bowel disease and gastroesophageal reflux disease. This suggests that SLC5A6 may be a useful indicator of the severity and progression of these disorders, and that targeting SLC5A6 may be a promising strategy for their diagnosis and treatment.

In conclusion, SLC5A6 is a unique and highly expressed protein that is characterized by its ability to bind to and label target tissues and organs due to its high affinity for calcium ions. Its expression pattern and involvement in several diseases make it a promising target for drug development and research. Further studies are needed to fully understand the role of SLC5A6 in biology and disease, and to develop new treatments based on this protein.

Protein Name: Solute Carrier Family 5 Member 6

Functions: Sodium-dependent multivitamin transporter that transports pantothenate, biotin and lipoate (PubMed:10329687, PubMed:15561972, PubMed:21570947, PubMed:20980265, PubMed:22927035, PubMed:22015582, PubMed:25971966, PubMed:25809983, PubMed:28052864, PubMed:27904971, PubMed:31754459). Required for biotin and pantothenate uptake in the instestine (By similarity). Plays a role in the maintenance of intestinal mucosa integrity, by providing the gut mucosa with biotin (By similarity). May play a role in the transport of biotin and pantothenate into the brain across the blood-brain barrier (PubMed:25809983). May also be involved in the sodium-dependent transport of iodide ions (PubMed:20980265)

The "SLC5A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC5A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets